Biotech Stock PepGen Inc. (Nasdaq: PEPG) Makes Top Gainer List on Third Quarter News and Corporate Highlights
PepGen Inc. (PEPG) reported Q3 2026 results, with stock up 148.49% on Nasdaq top gainers list. Positive topline results from Phase 2 FREEDOM2-DM1 trial for PGN-EDODM1 in DM1 patients showed 46.5% mean splicing correction. The company has $104.8M in cash and expects to fund operations into 2028. Net loss was $19.4M for Q3 2026.
How this was made
The 30-second read
Why it matters
The disclosed Phase 2 results provide the first efficacy readout for PGN‑EDODM1, a key catalyst for the company's valuation and future financing.
Market read
First disclosure of meaningful Phase 2 data for a rare‑disease therapy; likely to drive short‑term price movement and influence sector sentiment.
What to watch
Potential regulatory delays from the existing partial clinical hold and competition from other DM1 programs.
Background
PepGen is a clinical‑stage biotech focused on oligonucleotide therapies for rare genetic diseases, trading as a small‑cap on Nasdaq.
Ticker impact
PepGen reported positive Phase 2 FREEDOM2-DM1 trial data with 46.5% splicing correction and safety profile, a first disclosure of these results.
likely upward pressure as investors price in efficacy and potential partnership or licensing upside
First-time release of robust Phase 2 data for a rare disease therapy; biotech stocks typically rally on such milestones.
Market effects
May boost broader rare‑disease biotech sector and increase investor interest in oligonucleotide platforms.
Limited to US biotech market; no immediate regional effect.
Highlights progress in RNA‑targeted therapies, relevant to global biotech investors.
Counterpoint
If data does not translate to later‑stage success, the rally could be short‑lived; investors may wait for Phase 3 confirmation.
Key entities
- CompanyPepGen Inc.
Clinical‑stage biotech developing PGN‑EDODM1 for myotonic dystrophy type 1.
- ExecutiveJames McArthur
President and CEO of PepGen, quoted on trial results.
